Compare · MGRX vs VMD
MGRX vs VMD
Side-by-side comparison of Mangoceuticals Inc. (MGRX) and Viemed Healthcare Inc. (VMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGRX and VMD operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- VMD is the larger of the two at $346.6M, about 41.5x MGRX ($8.4M).
- MGRX has been more active in the news (12 items in the past 4 weeks vs 10 for VMD).
- VMD has more recent analyst coverage (2 ratings vs 0 for MGRX).
- Company
- Mangoceuticals Inc.
- Viemed Healthcare Inc.
- Price
- -
- -
- Market cap
- $8.4M
- $346.6M
- 1M return
- -
- -24.95%
- 1Y return
- -
- +29.08%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 12
- 10
- Recent ratings
- 0
- 2
Viemed Healthcare Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Latest MGRX
- Mangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form 425 filed by Mangoceuticals Inc.
- Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
- Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Mangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure
- Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
- SEC Form 425 filed by Mangoceuticals Inc.
Latest VMD
- Barrington Research initiated coverage on Viemed Healthcare with a new price target
- Viemed Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Heltz Sabrina converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 22% to 82,520 units (SEC Form 4)
- Director Dobbs Randy E. converted options into 20,954 shares and returned $37,468 worth of shares to the company (4,191 units at $8.94), increasing direct ownership by 13% to 142,253 units (SEC Form 4)
- Director Kaushal Nitin converted options into 18,786 shares, increasing direct ownership by 13% to 161,361 units (SEC Form 4)
- Director Smokoff Timothy converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 20% to 90,547 units (SEC Form 4)
- SEC Form S-8 filed by Viemed Healthcare Inc.
- SEC Form 10-Q filed by Viemed Healthcare Inc.
- Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viemed Healthcare Announces Second Quarter 2026 Financial Results